Quest Diagnostics Incorporated

Quest Diagnostics Incorporated

DGX·NYSE

$193.67

+0.26%
HealthcareMedical - Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

At a Glance

Live Snapshot
Market Cap$21.44B
EPS8.8700
P/E Ratio21.83
Earnings Date07/28/2026
8.43%
Return on Invested Capital
21%
3Y-14.0%
5Y-30.0%
10Y-
13.84%
Return on Equity
8%
3Y-14.0%
5Y-35.0%
10Y-1.0%
6.11%
Return on Assets
13%
3Y-17.0%
5Y-40.0%
10Y-4.0%
Quest Diagnostics Incorporated

Quest Diagnostics Incorporated Management Team

DGX · NYSE
MJ

Mr. James E. Davis

Chairman, Chief Executive Officer & President

Compensation

$3,321,508

Born 1963(Age 63)
male
MS

Mr. Sam A. Samad

Executive Vice President & Chief Financial Officer

Compensation

$1,340,233

Born 1970(Age 56)
male
MC

Ms. Catherine T. Doherty

Executive Vice President of Regional Businesses

Compensation

$1,142,487

Born 1963(Age 63)
female
MK

Ms. Kristin Lee Wallace Esq.

Senior Vice President & Chief Compliance Officer

female
MM

Mr. Michael E. Prevoznik J.D.

Senior Vice President & General Counsel

Compensation

$967,084

Born 1962(Age 64)
male
MM

Mr. Murali Balakumar

Senior Vice President and Chief Information & Digital Officer

male
MG

Mr. Garry Clark

Senior Vice President and Chief Marketing & Communications Officer

male
MK

Mr. Karthik Kuppusamy Ph.D.

Senior Vice President of Clinical Solutions

Compensation

$962,292

Born 1970(Age 56)
male
MM

Mr. Michael J. Deppe

Senior Vice President, Corporate Controller & Chief Accounting Officer

Born 1966(Age 60)
male
MS

Mr. Shawn C. Bevec

Vice President of Investor Relations

male
dgx

Quest Diagnostics Incorporated Insider Positioning

DGX · NYSE

During the last 12 months, insiders have sold $23.56M worth of DGX shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

10.0K

1.94M

Net Activity

-1.9M

-$1.94M

3-6 Months

Bought

0

0.00

Sold

46.2K

9.57M

Net Activity

-9.6M

-$9.57M

6-9 Months

Bought

0

0.00

Sold

47.4K

8.90M

Net Activity

-8.9M

-$8.90M

9-12 Months

Bought

0

0.00

Sold

17.9K

3.15M

Net Activity

-3.1M

-$3.15M

Top Buyers

No buying activity

Top Sellers

1
PME

Prevoznik Michael E

Officer: Svp & General Counsel

34.1K shares6 transactions

$6.49M

2
DJE

Davis J. E.

Director, Officer: Ceo And President

29.3K shares3 transactions

$5.86M

3
PP

Plewman Patrick

Officer: Svp For Diagnostic Services

20.3K shares8 transactions

$3.92M

4
DCT

Doherty Catherine T.

Officer: Evp, Regional Businesses

18.2K shares4 transactions

$3.74M

5
KK

Kuppusamy Karthik

Officer: Svp, Clinical Solutions

10.1K shares3 transactions

$1.79M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $23.56M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$1.94M

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

High Selling

5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.

SEC Filings

DGX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2026

N/A

April 06, 2026
May 20, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 04, 2025
May 15, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 05, 2024
May 16, 2024
2024
DEF 14A

DEF 14A

N/A

April 06, 2023
April 06, 2023
 
DEF 14A

DEF 14A 2022

N/A

April 19, 2022
May 18, 2022
2022
DEF 14A

DEF 14A 2021

N/A

April 09, 2021
May 21, 2021
2021
DEF 14A

DEF 14A 2020

N/A

April 08, 2020
May 19, 2020
2020
DEF 14A

DEF 14A 2019

N/A

April 03, 2019
May 14, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 04, 2018
May 15, 2018
2018
DEF 14A

DEF 14A 2017

N/A

April 05, 2017
May 16, 2017
2017
Showing 1 to 10 of 29 filings